Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
复制标题
DOI：
10.1002/bit.27945
复制
发表时间：
2022-01
影响因子：
3.8
通讯作者：
Douglas AD
中科院分区：
文献类型：
--
作者：
Joe CCD;Jiang J;Linke T;Li Y;Fedosyuk S;Gupta G;Berg A;Segireddy RR;Mainwaring D;Joshi A;Cashen P;Rees B;Chopra N;Nestola P;Humphreys J;Davies S;Smith N;Bruce S;Verbart D;Bormans D;Knevelman C;Woodyer M;Davies L;Cooper L;Kapanidou M;Bleckwenn N;Pappas D;Lambe T;Smith DC;Green CM;Venkat R;Ritchie AJ;Gilbert SC;Turner R;Douglas AD
在新冠肺炎大流行期间，制造业一直是限制疫苗接种推广的关键因素，需要快速开发和大规模实施新的制造技术。ChAdOx1nCoV-19(AZD1222，Vaxzevria)是一种基于腺病毒载体的SARS-CoV-2疫苗。我们描述了这种疫苗和基于同一平台的其他疫苗的生产过程的发展，包括促进超大规模生产的新特征。我们讨论了过程经济学和我们为在全球相关规模和国际供应安全的情况下提供疫苗而采取的“分布式制造”方法。这些方法加在一起，实现了迄今为止规模最大的病毒载体制造活动，以低成本提供了全球新冠肺炎疫苗供应的相当大比例。牛津大学和阿斯利康开发的ChAdOx1 nCoV-19疫苗已经以低成本生产和分销了超过10亿剂。到目前为止，这占全球新冠肺炎疫苗供应的很大比例，特别是在低收入和中等收入国家。作者报告了疫苗制造工艺的发展，以及涉及五大洲散装疫苗(药物)生产的过程经济学和分布式制造方法。
Manufacturing has been the key factor limiting rollout of vaccination during the COVID‐19 pandemic, requiring rapid development and large‐scale implementation of novel manufacturing technologies. ChAdOx1 nCoV‐19 (AZD1222, Vaxzevria) is an efficacious vaccine against SARS‐CoV‐2, based upon an adenovirus vector. We describe the development of a process for the production of this vaccine and others based upon the same platform, including novel features to facilitate very large‐scale production. We discuss the process economics and the “distributed manufacturing” approach we have taken to provide the vaccine at globally‐relevant scale and with international security of supply. Together, these approaches have enabled the largest viral vector manufacturing campaign to date, providing a substantial proportion of global COVID‐19 vaccine supply at low cost. Well over a billion doses of the ChAdOx1 nCoV‐19 vaccine developed by The University of Oxford and AstraZeneca have been produced and distributed at low cost. This represents a substantial proportion of global COVID‐19 vaccine supply to date, especially in low‐ and middle‐income countries. The authors report on the development of the manufacturing process for the vaccine, and the process economics and distributed manufacturing approach involving bulk vaccine (drug substance) production on five continents.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
Chadox1 NCOV-19疫苗可防止恒河猕猴中的SARS-COV-2肺炎。
影响因子：
64.8
作者：
van Doremalen N;Lambe T;Spencer A;Belij-Rammerstorfer S;Purushotham JN;Port JR;Avanzato VA;Bushmaker T;Flaxman A;Ulaszewska M;Feldmann F;Allen ER;Sharpe H;Schulz J;Holbrook M;Okumura A;Meade-White K;Pérez-Pérez L;Edwards NJ;Wright D;Bissett C;Gilbride C;Williamson BN;Rosenke R;Long D;Ishwarbhai A;Kailath R;Rose L;Morris S;Powers C;Lovaglio J;Hanley PW;Scott D;Saturday G;de Wit E;Gilbert SC;Munster VJ
通讯作者：
Munster VJ
影响因子：
5.5
作者：
Fedosyuk, Sofiya;Merritt, Thomas;Douglas, Alexander D.
通讯作者：
Douglas, Alexander D.
影响因子：
4.2
作者：
Yao, F;Svensjö, T;Eriksson, E
通讯作者：
Eriksson, E
DOI：
10.5731/pdajpst.2013.00910
发表时间：
2013-03-01
影响因子：
--
作者：
Yang, Harry
通讯作者：
Yang, Harry